January 7, 2019 07:11 AM ESTUpdated 08:28 AM
Deals

#JPM19 starts with Eli Lil­ly's $8B buy­out of Loxo On­col­o­gy — so who's next?

John Carroll

Editor & Founder

Eli Lil­ly $LLY has paid $8 bil­lion to jump the queue and take a lead­ing role in an emerg­ing — though still small — field of on­col­o­gy.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

TRENDING NOW

Full TIG­IT da­ta from Gilead, Ar­cus show low­er PFS rates than De­cem­ber read­out: #AS­CO23

Bris­tol My­er­s' Op­di­vo keeps can­cer at bay in more lym­phoma pa­tients than Seagen's Ad­cetris in PhI­II: #AS­CO23

Servi­er’s vo­rasi­denib stalls pro­gres­sion of brain can­cer by 61% in piv­otal PhI­II IN­DI­GO study: #AS­CO23

As­traZeneca tri­al shows mod­est ben­e­fit in ovar­i­an can­cer, but doc­tors say it's hard to ap­ply find­ings: #AS­CO23

No­vo Nordisk un­veils $165M buy­out bid for a drug de­liv­ery part­ner on smart in­sulin pens

sponsored

The new rules of can­cer care: Re­spond­ing to in­creas­ing CMS in­flu­ence on the on­col­o­gy land­scape

A service from the Financial Times